human | Q5 |
P496 | ORCID iD | 0000-0001-9795-5644 |
P735 | given name | John | Q4925477 |
John | Q4925477 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q92290257 | A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals |
Q92111772 | Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers |
Q40145604 | Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. |
Q92596446 | Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data |
Q37042256 | CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer |
Q47576454 | CRISPR Libraries and Screening. |
Q40336402 | Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. |
Q91838895 | Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations |
Q53316010 | Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. |
Q42740602 | Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy. |
Q36042596 | DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. |
Q36036608 | Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens |
Q97686528 | Emergence of a High-Plasticity Cell State during Lung Cancer Evolution |
Q97535525 | Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer |
Q35238397 | Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer |
Q49832498 | Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. |
Q99552320 | Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors |
Q100535021 | Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks |
Q112702380 | Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts |
Q90659981 | HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers |
Q53400102 | Histone Code Aberrancies in Small Cell Lung Cancer. |
Q91839128 | Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids |
Q41992348 | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. |
Q96431247 | Lineage reversion drives WNT independence in intestinal cancer |
Q92377180 | MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer |
Q43627373 | MYC, MAX, and small cell lung cancer. |
Q92709040 | Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data |
Q90680882 | NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination |
Q89527853 | New Approaches to SCLC Therapy: From the Laboratory to the Clinic |
Q39934413 | Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. |
Q40208474 | Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer |
Q60907546 | ONECUT2 is a driver of neuroendocrine prostate cancer |
Q37339265 | P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. |
Q40640808 | PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. |
Q64229921 | Peptide-based PET quantifies target engagement of PD-L1 therapeutics |
Q35224606 | Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group |
Q92720881 | Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts |
Q57181405 | ProteomeGenerator: A framework for comprehensive proteomics based on de novo transcriptome assembly and high-accuracy peptide mass spectral matching |
Q36128151 | Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis |
Q35170413 | RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer |
Q41848124 | RET mutations in neuroendocrine tumors: including small-cell lung cancer |
Q35878431 | Rapamycin rescues ABT-737 efficacy in small cell lung cancer |
Q89637977 | Regenerative lineages and immune-mediated pruning in lung cancer metastasis |
Q112708650 | Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer |
Q37463325 | Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. |
Q35662216 | Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy |
Q52813956 | Small-cell lung cancer in 2016: Shining light on novel targets and therapies. |
Q100535047 | TMEM41B is a pan-flavivirus host factor |
Q57462253 | Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts |
Q48251246 | Target engagement imaging of PARP inhibitors in small-cell lung cancer. |
Q38791259 | Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts. |
Q63866205 | Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition |
Q112350511 | ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer |
Q38769421 | Unravelling the biology of SCLC: implications for therapy |
Q39776608 | Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. |
Q90414077 | Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development |
Q91388498 | Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development |
Search more.